Next Generation Drug Conjugates Market: OVERVIEW
As per Roots Analysis, the global next generation drug conjugates market is estimated to grow from USD 3.3 billion in the current year to USD 15.47 billion by 2035, at a CAGR of 15.07% during the forecast period, till 2035.
The market sizing and opportunity analysis has been segmented across the following parameters:
Type of Next Generation Drug Conjugates
Peptide Receptor Radionuclide Therapy (Peptide Radionuclide Conjugate)
Ligand Mediated RNAi Conjugate
Ligand Conjugated Anti Sense Medicine
Peptide Drug Conjugate
Type of Targeting Ligand
Amino Sugar
Lipid
Peptide
Type of Payload
Si-RNA
Antisense Oligonucleotide
Radionuclide
Drug
Type of Therapy
Monotherapy
Combination Therapy
Route of Administration
Intravenous
Subcutaneous
Key Target Indications
Gastroenteropancreatic Neuroendocrine Tumors
Prostate Cancer
Leptomeningeal Carcinomatosis caused by Breast Cancer Brain Metastases
Hereditary Transthyretin Amyloidosis
Atherosclerotic Cardiovascular Diseases
Severe Hypertriglyceridemia
Hereditary Angioedema
Acute Hepatic Porphyria
Primary Hyperoxaluria
Heterozygous Familial Hypercholesterolemia
Hemophilia
Low-Risk Myelodysplastic Syndrome
Myelofibrosis
Alpha-1 Antitrypsin Deficiency Liver Disease
Familial Chylomicronemia Syndrome
Key Geographical Regions
North America
Europe
Asia-Pacific
Rest of the World
NEXT GENERATION DRUG CONJUGATES MARKET: GROWTH AND TRENDS
Owing to their non-immunogenic nature, structural stability, better clinical profile, targeted delivery of payload, limited side effects, permeability and deeper cellular penetration, next generation drug conjugates have emerged as viable targeted therapeutics for rare disease indications, including cancers. Similar to antibody drug conjugates (ADCs), these advanced versions boast superior clinical efficacy and stability while employing diverse non-antibody targeting agents, such as peptides, amino sugars, lipids, and small molecules. Instead of traditional drugs, they use payloads, such as oligonucleotides, antisense oligonucleotides, si-RNA, drugs, and radionuclides for targeted delivery. This fusion of targeting ligands and payloads has spawned various types of next generation drug conjugates, including peptide drug conjugates, peptide receptor radionuclide therapy, GalNac conjugates, si-RNA conjugates, all proving effective against diseases, such as solid tumors, metabolic disorders, and hematological disorders.
The USFDA has approved six next generation drug conjugates for therapeutic use, including Lutathera®, Pluvicto®, Givlaari®, Oxlumo®, Leqvio®, and Amvuttra®. These approvals underscore the clinical triumphs of these advanced therapies and their potential across a wide range of medical conditions. With ongoing innovation, promising trial outcomes, expedited approvals, and collaborative efforts, the market for next generation drug conjugates anticipates significant growth in the forecast period.
NEXT GENERATION DRUG CONJUGATES MARKET: KEY INSIGHTS
The report delves into the current state of the next generation drug conjugates market and identifies potential growth opportunities within the industry. Some key findings from the report include:
1. The pipeline features more than 200 next generation drug conjugates with small molecules, peptides, lipids, amino sugars and virus like particles as the targeting ligands for therapeutic purposes.
2. Close to 60% of the next generation drug conjugates use peptides as targeting ligands; of these, the majority are being evaluated in clinical trials for the treatment of oncological disorders.
3. Over 260 clinical trials have been registered in the past few years to evaluate the safety and efficacy of various next generation drug conjugates; majority of these studies have been conducted across sites in the US.
4. Over the past few years, partnership activity in this field has increased for the development of effective drug conjugate therapies.
5. Lack of clinical efficacy has been the common reason for drug failure, accounting for the discontinuation of more than 55% of clinical trials, while several non-drug related issues caused the failure of more than 30% of trials.
6. With growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of over 20%, during the next decade.
NEXT GENERATION DRUG CONJUGATES MARKET: KEY SEGMENTS
Ligand Mediated RNAi Conjugate Occupies the Largest Share of the Next Generation Drug Conjugates Market
Based on the type of next generation drug conjugates, the market is segmented into ligand mediated RNAi conjugate, peptide-radionuclide conjugate, ligand conjugated anti sense medicine and peptide drug conjugate. Currently, ligand mediated RNAi conjugate holds the maximum share of the next generation drug conjugates market. It is worth highlighting that the next generation drug conjugates for ligand conjugated anti sense medicine is likely to grow at a relatively higher CAGR.
Amino Sugar is Likely to Dominate the Next Generation Drug Conjugates Market in the Coming Decade
Based on the targeting ligand, the market is segmented into amino sugar, lipids and peptide. At present, peptide captures the highest portion of the next generation drug conjugates market. However, in the near future, the next generation drug conjugates market is likely to be driven by amino sugar.
Radionuclides Occupy the Largest Share of the Next Generation Drug Conjugates
Based on payload, the market is segmented into si-RNA, radionuclide, antisense oligonucleotide and drug. At present, radionuclide holds the maximum share of the next generation drug conjugates market. It is worth highlighting that the next generation drug conjugates for si-RNA is likely to grow at a relatively higher CAGR.
Combination Therapies are Likely to Dominate the Next Generation Drug Conjugates Market During the Forecast Period
Based on the type of therapy, the market is segmented into monotherapy and combination therapy. Currently, combination therapy holds the maximum share of the next generation drug conjugates market. This trend is unlikely to change in the coming decades.
Intravenous Route Occupies the Largest Share of the Next Generation Drug Conjugates Market
Based on the route of administration, the market is segmented into intravenous and subcutaneous. The intravenous mode of drug delivery captures the highest share of the current next generation drug conjugates market. However, the next generation drug conjugates market for subcutaneous route is likely to grow at a relatively higher CAGR in the coming decade.
The Hemophilia Segment is the Fastest Growing Segment of the Next Generation Drug Conjugates Market During the Forecast Period
Based on the key target disease indication, the market is segmented into gastroenteropancreatic neuroendocrine tumors, prostate cancer, leptomeningeal carcinomatosis caused by breast cancer brain metastases, hereditary transthyretin amyloidosis, atherosclerotic cardiovascular diseases, severe hypertriglyceridemia, hereditary angioedema, acute hepatic porphyria, primary hyperoxaluria, heterozygous familial hypercholesterolemia, hemophilia, low-risk myelodysplastic syndrome, myelofibrosis, alpha-1 antitrypsin deficiency liver disease and familial chylomicronemia syndrome. It is worth highlighting that, at present, prostate cancer holds a higher share of the next generation drug conjugates market. However, the next generation drug conjugates market for hemophilia is likely to grow at a relatively higher CAGR.
North America Accounts for the Largest Share of the Market
Based on key geographical regions, the market is segmented into North America, Europe, and Asia-Pacific and the Rest of the World. The majority share is expected to be captured by players based in North America. It is worth highlighting that, over the years, the market in Asia-Pacific and the Rest of the World is expected to grow at a higher CAGR.
Example Players in the Next Generation Drug Conjugates Market
Advanced Accelerator Applications
Alnylam Pharmaceuticals
Arrowhead Pharmaceuticals
Dicerna Pharmaceuticals
Geron Corporation
Ionis Pharmaceuticals
NEXT GENERATION DRUG CONJUGATES MARKET: RESEARCH COVERAGE
Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the next generation drug conjugates market, focusing on key market segments, including [A] type of targeting ligand, [B] type of payload, [C] type of therapy, [D] route of administration, [E] target disease indication and [F] key geographical regions.
Market Landscape: A comprehensive evaluation of next generation drug conjugates / next generation targeted therapeutics that are either approved or being evaluated in different stages of development, considering various parameters, such as [A] type of conjugate, [B] type of targeting ligand, [C] type of payload, [D] type of biological target, [E] mechanism of action, [F] stage of development, [G] phase of development, [H] type of therapy, [I] route of administration, [J] target disease indication, [K] therapeutic area and [L] target population. Further, the chapter includes information on various next generation drug conjugate developers, based on their [M] year of establishment, [N] company size, [O] location of headquarters and [P] most active players (in terms of number of drug candidates).
Company Profiles: In-depth profiles of key industry players involved in the development of next generation drug conjugates, focusing on [A] company overviews, [B] product portfolio, [C] detailed information on the drug candidates which are either approved or are in phase III of clinical development, [D] recent developments and [E] an informed future outlook.
Clinical Trials: Examination of completed, ongoing, and planned clinical studies of various drug conjugates based on parameters like [A] trial registration year, [B] trial phase, [C] trial status, [D] enrolled patient population, [E] type of sponsor, [F] age group, [G] most active industry players, [H] leading drug candidate, [I] primary purpose, [J] therapeutic area and [K] key geographical regions.
Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2018, covering acquisitions, research and development agreements, product development and commercialization agreements, platform / technology licensing agreement, service agreements, clinical trial agreements, joint ventures and others.
Academic Grant Analysis: A comprehensive evaluation of various grants that have been awarded to research institutes engaged in conducting research related to next generation drug conjugates, since 2018, based on various important parameters, such as [A] year of grant award, [B] amount awarded, [C] funding institute center, [D] support period, [E] type of grant application, [F] purpose of grant award, [G] activity code, [H] study section involved, [I] popular NIH departments (based on number of grants awarded), [J] prominent program officers, [K] leading recipient organizations and [L] key regions.
Publication Analysis: An in-depth analysis of scientific articles focused on next generation drug conjugates based on [A] year of publication, [B] type of publication, [C] type of conjugate, [D] target indication, [C] copyright holders, [D] focus area, [E] leading publishers and [F] key journals (in terms of number of articles published and impact factor).
Drug Failure Analysis: An in-depth analysis of next generation drug conjugates that failed to progress to later stages of development, based on various relevant parameters, such as trial status of discontinuation, trial phase of discontinuation, average trial year, type of therapy, target indication and reason for drug failure.
Success Protocol Analysis: An insightful success protocol analysis of recently approved and commercialized next generation drug conjugates, based on several relevant parameters, such as dosing frequency, drug efficacy, drug exclusivity, drug designation, fatality rate, geographical reach, intra-class competition, line of treatment, prevalence, price, type of therapy, and existing competition among developers.
KEY QUESTIONS ANSWERED IN THIS REPORT
How many companies are currently engaged in this market?
Which are the leading companies in this market?
What kind of partnership models are commonly adopted by industry stakeholders?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?
REASONS TO BUY THIS REPORT
The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
ADDITIONAL BENEFITS
Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
Free Updated report if the report is 6-12 months old or older
Next Generation Drug Conjugates Market: OVERVIEW
As per Roots Analysis, the global next generation drug conjugates market is estimated to grow from USD 3.3 billion in the current year to USD 15.47 billion by 2035, at a CAGR of 15.07% during the forecast period, till 2035.
The market sizing and opportunity analysis has been segmented across the following parameters:
Type of Next Generation Drug Conjugates
Peptide Receptor Radionuclide Therapy (Peptide Radionuclide Conjugate)
Ligand Mediated RNAi Conjugate
Ligand Conjugated Anti Sense Medicine
Peptide Drug Conjugate
Type of Targeting Ligand
Amino Sugar
Lipid
Peptide
Type of Payload
Si-RNA
Antisense Oligonucleotide
Radionuclide
Drug
Type of Therapy
Monotherapy
Combination Therapy
Route of Administration
Intravenous
Subcutaneous
Key Target Indications
Gastroenteropancreatic Neuroendocrine Tumors
Prostate Cancer
Leptomeningeal Carcinomatosis caused by Breast Cancer Brain Metastases
Hereditary Transthyretin Amyloidosis
Atherosclerotic Cardiovascular Diseases
Severe Hypertriglyceridemia
Hereditary Angioedema
Acute Hepatic Porphyria
Primary Hyperoxaluria
Heterozygous Familial Hypercholesterolemia
Hemophilia
Low-Risk Myelodysplastic Syndrome
Myelofibrosis
Alpha-1 Antitrypsin Deficiency Liver Disease
Familial Chylomicronemia Syndrome
Key Geographical Regions
North America
Europe
Asia-Pacific
Rest of the World
NEXT GENERATION DRUG CONJUGATES MARKET: GROWTH AND TRENDS
Owing to their non-immunogenic nature, structural stability, better clinical profile, targeted delivery of payload, limited side effects, permeability and deeper cellular penetration, next generation drug conjugates have emerged as viable targeted therapeutics for rare disease indications, including cancers. Similar to antibody drug conjugates (ADCs), these advanced versions boast superior clinical efficacy and stability while employing diverse non-antibody targeting agents, such as peptides, amino sugars, lipids, and small molecules. Instead of traditional drugs, they use payloads, such as oligonucleotides, antisense oligonucleotides, si-RNA, drugs, and radionuclides for targeted delivery. This fusion of targeting ligands and payloads has spawned various types of next generation drug conjugates, including peptide drug conjugates, peptide receptor radionuclide therapy, GalNac conjugates, si-RNA conjugates, all proving effective against diseases, such as solid tumors, metabolic disorders, and hematological disorders.
The USFDA has approved six next generation drug conjugates for therapeutic use, including Lutathera®, Pluvicto®, Givlaari®, Oxlumo®, Leqvio®, and Amvuttra®. These approvals underscore the clinical triumphs of these advanced therapies and their potential across a wide range of medical conditions. With ongoing innovation, promising trial outcomes, expedited approvals, and collaborative efforts, the market for next generation drug conjugates anticipates significant growth in the forecast period.
NEXT GENERATION DRUG CONJUGATES MARKET: KEY INSIGHTS
The report delves into the current state of the next generation drug conjugates market and identifies potential growth opportunities within the industry. Some key findings from the report include:
1. The pipeline features more than 200 next generation drug conjugates with small molecules, peptides, lipids, amino sugars and virus like particles as the targeting ligands for therapeutic purposes.
2. Close to 60% of the next generation drug conjugates use peptides as targeting ligands; of these, the majority are being evaluated in clinical trials for the treatment of oncological disorders.
3. Over 260 clinical trials have been registered in the past few years to evaluate the safety and efficacy of various next generation drug conjugates; majority of these studies have been conducted across sites in the US.
4. Over the past few years, partnership activity in this field has increased for the development of effective drug conjugate therapies.
5. Lack of clinical efficacy has been the common reason for drug failure, accounting for the discontinuation of more than 55% of clinical trials, while several non-drug related issues caused the failure of more than 30% of trials.
6. With growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of over 20%, during the next decade.
NEXT GENERATION DRUG CONJUGATES MARKET: KEY SEGMENTS
Ligand Mediated RNAi Conjugate Occupies the Largest Share of the Next Generation Drug Conjugates Market
Based on the type of next generation drug conjugates, the market is segmented into ligand mediated RNAi conjugate, peptide-radionuclide conjugate, ligand conjugated anti sense medicine and peptide drug conjugate. Currently, ligand mediated RNAi conjugate holds the maximum share of the next generation drug conjugates market. It is worth highlighting that the next generation drug conjugates for ligand conjugated anti sense medicine is likely to grow at a relatively higher CAGR.
Amino Sugar is Likely to Dominate the Next Generation Drug Conjugates Market in the Coming Decade
Based on the targeting ligand, the market is segmented into amino sugar, lipids and peptide. At present, peptide captures the highest portion of the next generation drug conjugates market. However, in the near future, the next generation drug conjugates market is likely to be driven by amino sugar.
Radionuclides Occupy the Largest Share of the Next Generation Drug Conjugates
Based on payload, the market is segmented into si-RNA, radionuclide, antisense oligonucleotide and drug. At present, radionuclide holds the maximum share of the next generation drug conjugates market. It is worth highlighting that the next generation drug conjugates for si-RNA is likely to grow at a relatively higher CAGR.
Combination Therapies are Likely to Dominate the Next Generation Drug Conjugates Market During the Forecast Period
Based on the type of therapy, the market is segmented into monotherapy and combination therapy. Currently, combination therapy holds the maximum share of the next generation drug conjugates market. This trend is unlikely to change in the coming decades.
Intravenous Route Occupies the Largest Share of the Next Generation Drug Conjugates Market
Based on the route of administration, the market is segmented into intravenous and subcutaneous. The intravenous mode of drug delivery captures the highest share of the current next generation drug conjugates market. However, the next generation drug conjugates market for subcutaneous route is likely to grow at a relatively higher CAGR in the coming decade.
The Hemophilia Segment is the Fastest Growing Segment of the Next Generation Drug Conjugates Market During the Forecast Period
Based on the key target disease indication, the market is segmented into gastroenteropancreatic neuroendocrine tumors, prostate cancer, leptomeningeal carcinomatosis caused by breast cancer brain metastases, hereditary transthyretin amyloidosis, atherosclerotic cardiovascular diseases, severe hypertriglyceridemia, hereditary angioedema, acute hepatic porphyria, primary hyperoxaluria, heterozygous familial hypercholesterolemia, hemophilia, low-risk myelodysplastic syndrome, myelofibrosis, alpha-1 antitrypsin deficiency liver disease and familial chylomicronemia syndrome. It is worth highlighting that, at present, prostate cancer holds a higher share of the next generation drug conjugates market. However, the next generation drug conjugates market for hemophilia is likely to grow at a relatively higher CAGR.
North America Accounts for the Largest Share of the Market
Based on key geographical regions, the market is segmented into North America, Europe, and Asia-Pacific and the Rest of the World. The majority share is expected to be captured by players based in North America. It is worth highlighting that, over the years, the market in Asia-Pacific and the Rest of the World is expected to grow at a higher CAGR.
Example Players in the Next Generation Drug Conjugates Market
Advanced Accelerator Applications
Alnylam Pharmaceuticals
Arrowhead Pharmaceuticals
Dicerna Pharmaceuticals
Geron Corporation
Ionis Pharmaceuticals
NEXT GENERATION DRUG CONJUGATES MARKET: RESEARCH COVERAGE
Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the next generation drug conjugates market, focusing on key market segments, including [A] type of targeting ligand, [B] type of payload, [C] type of therapy, [D] route of administration, [E] target disease indication and [F] key geographical regions.
Market Landscape: A comprehensive evaluation of next generation drug conjugates / next generation targeted therapeutics that are either approved or being evaluated in different stages of development, considering various parameters, such as [A] type of conjugate, [B] type of targeting ligand, [C] type of payload, [D] type of biological target, [E] mechanism of action, [F] stage of development, [G] phase of development, [H] type of therapy, [I] route of administration, [J] target disease indication, [K] therapeutic area and [L] target population. Further, the chapter includes information on various next generation drug conjugate developers, based on their [M] year of establishment, [N] company size, [O] location of headquarters and [P] most active players (in terms of number of drug candidates).
Company Profiles: In-depth profiles of key industry players involved in the development of next generation drug conjugates, focusing on [A] company overviews, [B] product portfolio, [C] detailed information on the drug candidates which are either approved or are in phase III of clinical development, [D] recent developments and [E] an informed future outlook.
Clinical Trials: Examination of completed, ongoing, and planned clinical studies of various drug conjugates based on parameters like [A] trial registration year, [B] trial phase, [C] trial status, [D] enrolled patient population, [E] type of sponsor, [F] age group, [G] most active industry players, [H] leading drug candidate, [I] primary purpose, [J] therapeutic area and [K] key geographical regions.
Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2018, covering acquisitions, research and development agreements, product development and commercialization agreements, platform / technology licensing agreement, service agreements, clinical trial agreements, joint ventures and others.
Academic Grant Analysis: A comprehensive evaluation of various grants that have been awarded to research institutes engaged in conducting research related to next generation drug conjugates, since 2018, based on various important parameters, such as [A] year of grant award, [B] amount awarded, [C] funding institute center, [D] support period, [E] type of grant application, [F] purpose of grant award, [G] activity code, [H] study section involved, [I] popular NIH departments (based on number of grants awarded), [J] prominent program officers, [K] leading recipient organizations and [L] key regions.
Publication Analysis: An in-depth analysis of scientific articles focused on next generation drug conjugates based on [A] year of publication, [B] type of publication, [C] type of conjugate, [D] target indication, [C] copyright holders, [D] focus area, [E] leading publishers and [F] key journals (in terms of number of articles published and impact factor).
Drug Failure Analysis: An in-depth analysis of next generation drug conjugates that failed to progress to later stages of development, based on various relevant parameters, such as trial status of discontinuation, trial phase of discontinuation, average trial year, type of therapy, target indication and reason for drug failure.
Success Protocol Analysis: An insightful success protocol analysis of recently approved and commercialized next generation drug conjugates, based on several relevant parameters, such as dosing frequency, drug efficacy, drug exclusivity, drug designation, fatality rate, geographical reach, intra-class competition, line of treatment, prevalence, price, type of therapy, and existing competition among developers.
KEY QUESTIONS ANSWERED IN THIS REPORT
How many companies are currently engaged in this market?
Which are the leading companies in this market?
What kind of partnership models are commonly adopted by industry stakeholders?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?
REASONS TO BUY THIS REPORT
The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
ADDITIONAL BENEFITS
Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
Free Updated report if the report is 6-12 months old or older
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook